Aileron Therapeutics

Aileron Therapeutics saw a 38.1% drop in short interest to 110,600 shares by December 15th. Shares opened at $2.25, with a market cap of $48.75M and a -0.72 P/E ratio. Hedge funds adjusted holdings, with institutional investors owning 90.89% of stock. The company focuses on developing LTI-03 for idiopathic pulmonary fibrosis.

Aileron Therapeutics (NASDAQ: ALRN) develops first-in-class medicines for orphan pulmonary and fibrosis indications, focusing on ALRN-6924 (chemoprotective agent) and LTI-03 (Caveolin-1-related peptide for IPF). Following a terminated Phase 1b breast cancer trial, Aileron acquired Lung Therapeutics, Inc. and secured $18M in funding. Led by new CEO Dr. Brian Windsor, Aileron aims to advance its therapeutic candidates.